| Literature DB >> 34610293 |
Lisa Osbelt1, Marie Wende1, Éva Almási2, Elisabeth Derksen2, Uthayakumar Muthukumarasamy2, Till R Lesker2, Eric J C Galvez2, Marina C Pils3, Enrico Schalk4, Patrick Chhatwal5, Jacqueline Färber6, Meina Neumann-Schaal7, Thomas Fischer8, Dirk Schlüter9, Till Strowig10.
Abstract
Gut colonization with multidrug-resistant (MDR) bacteria enhances the risk of bloodstream infections in susceptible individuals. We demonstrate highly variable degrees of ex vivo colonization resistance against a carbapenem-resistant Klebsiella pneumoniae strain in human feces samples and subsequently isolate diverse K. oxytoca strains from protected donors. Several of these K. oxytoca strains reduce gut colonization of MDR K. pneumoniae strains in antibiotic-treated and gnotobiotic mouse models. Comparative analysis of K. oxytoca strains coupled with CRISPR-Cas9-mediated deletion of casA, a protein essential for utilization of selected beta-glucosides, identified competition for specific carbohydrates as key in promoting colonization resistance. In addition to direct competition between K. oxytoca and K. pneumoniae, cooperation with additional commensals is required to reestablish full colonization resistance and gut decolonization. Finally, humanized microbiota mice generated from K. pneumoniae-susceptible donors are protected by K. oxytoca administration, demonstrating the potential of commensal K. oxytoca strains as next-generation probiotics.Entities:
Keywords: 16S rRNA gene sequencing; Klebsiella oxytoca; Klebsiella pneumoniae; beta-glucosides; colonization resistance; enteric infections; humanized mouse models; intestinal microbiota; multidrug-resistant bacteria; probiotics
Mesh:
Substances:
Year: 2021 PMID: 34610293 DOI: 10.1016/j.chom.2021.09.003
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 21.023